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Background/aim: In this study, we aimed to assess the clinical and immunological findings of our patients with common variable
immunodeficiency (CVID).
Materials and methods: We analyzed the records of 31 adult patients with CVID (12 females, 19 males). The patients were classified
into clinical and immunophenotypic subgroups for statistical comparisons.
Results: Our patients had some clinical signs in considerable frequencies, such as low body weight (45.2%), urinary tract infections
(41.9%), various dermatoses (35.5%), and oral aphthae (32.3%). The histological findings in the biopsy specimens of the gastrointestinal
tract (nodular lymphoid hyperplasia, villous atrophy, and lymphocytic infiltrates at mucosa) were significantly associated with
splenomegaly, hepatomegaly, or low body weight (P = 0.005, 0.045, and 0.007, respectively). The patients with low CD4/CD8 ratios
had lower IgG levels and a lower percentage of CD19+ B cells, but a higher percentage of activated T cells (P = 0.023, 0.011, and 0.028,
respectively).
Conclusion: In adults with CVID, there existed some clinical signs at considerable frequencies, but these are not overemphasized in the
literature. The CD4/CD8 ratio is an important factor in antibody production and the clinical presentation of CVID. It seems that the
adaptive immune system is on alert and subclinical immune activation insidiously continues in patients with CVID.
Key words: Immunodeficiencies, immunophenotype, classification of common variable immunodeficiency

1. Introduction
Common variable immunodeficiency (CVID) is a
mysterious primary immunodeficiency disorder (PID)
characterized by impaired immunoglobulin production
and an unpredictable clinical course (1). Two peaks in
childhood (before the age of 10 years) and adulthood
(between 30 and 40 years of age) are seen for this
disorder. In spite of recent improvements in diagnostic
tools, the diagnosis of mild or moderate CVID is often
delayed, especially in adult patients, due to the lack of
awareness of this illness among medical professionals.
The most remarkable clinical feature of CVID is recurrent

infections. Some autoimmune diseases, allergies, and
malignant conditions are the other frequent clinical
associations. The prevalence of CVID is the second most
common among the PIDs, which is between 1/25,000
and 50,000. In spite of many clinical and laboratory
investigations, the current knowledge of CVID is not
enough to clarify its pathogenesis. Mutations in the genes
ICOS (inducible T-cell co-stimulator on chromosome 2q),
TACI (transmembrane activator and CAML-interactor
on chromosome 17p), BAFF (B-cell activating factor on
chromosome 22q), and CD19 (on chromosome 16p) were
identified in only a small proportion of patients with CVID

* Data from this study were presented as a poster at the 21st National Allergy and Immunology Congress, 25–29 October 2014,
		 Bodrum, Turkey.
** Correspondence: fevzidemirel@yahoo.com.tr
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(2). While a familial transmission pattern of the disease is
seen in about 10% of patients, a sporadic pattern of disease
occurs in most of the patients (3).
Studies focusing on the clinical and immunological
phenotypes of CVID revealed some considerable
relationships among certain findings (4). Accordingly,
the Freiburg, Paris, and EUROClass research groups
suggested some classification schemes for CVID. Briefly,
these classification systems were developed on the basis
of B-cell phenotypes and clinical properties. It is clearly
predictable that these schemes will be applied to improve
the management of this complex disorder.
We believe that all PID centers should analyze their
experiences related to CVID and share their findings.
Thus, the accumulated data would provide the most
convenient and practical approach for the evaluation and
management of patients with CVID. Therefore, we herein
aimed to assess the clinical and immunological findings
of our own patients with CVID and to reveal possible
relationships by their analysis.
2. Materials and methods
2.1. Patients
We retrospectively analyzed the records of 31 adult patients
with CVID (19 males, 12 females) who were referred
to our clinic by their primary care physicians between
January 2008 and May 2014. At their first visit, 7 patients
were already diagnosed with CVID by another center
and were receiving intravenous immunoglobulin (IVIG)
treatment, and 7 other patients had CVID diagnosis
without IVIG treatment. Seventeen patients with CVID
were diagnosed by our clinic after their follow-up period.
The European Society of Immune Deficiencies (ESID)
and the Pan American Group for Immune Deficiency
(PAGID) diagnostic criteria were used for the diagnosis
of CVID (5). According to these criteria, patients who
have markedly reduced serum immunoglobulin (Ig) G
concentrations in combination with low levels of serum
IgA and/or IgM should fulfill all of the following criteria: a)
more than 2 years of age at the onset of immunodeficiency,
b) absence of isohemagglutinins and/or poor response
to vaccines, and c) exclusion of other causes leading to
hypogammaglobulinemia. All patients completed the
questionnaires specifically prepared for CVID. The study
was conducted according to the Helsinki Declaration.
Ethics committee approval and informed consent of the
patients were received in accordance with the procedure.
2.2. Physical measurement
Ideal body weights (IBWs) of the patients were calculated
via the IBW formula [50 kg + 0.9 kg/each cm over 152 cm
(–4.5 kg if female)] (6). A weight of less than the IBW was
considered a low body weight.
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2.3. Immunological analyses
While immunoglobulin (IgG, IgA, IgM) and complement
(C3c, C4) levels in sera were measured via a nephelometer
(Siemens Healthcare Diagnostics, BN II system),
lymphocyte subsets were determined in peripheral
blood samples with EDTA using flow cytometry (Becton
Dickinson, FACSCanto system). As per the manufacturers’
instructions, kits compatible with the devices were used
for these analyses. The absolute counts of each of the
lymphocyte subsets (number of cells/μL) were calculated
with the following formula: white blood cell (WBC) count
× lymphocyte percentage × lymphocyte subset percentage
(7).
2.4. Biochemical analyses
Complete blood counts and blood tests for measurements
of alanine transaminase (ALT), aspartate transaminase
(AST), alkaline phosphatase (ALP), gamma glutamyl
transpeptidase (GGT), vitamin B12, folate, and ferritin
levels were performed with appropriate methods in the
biochemistry department of our institute.
2.5. Statistical analysis
Commercial statistical software (SPSS 11.5, SPSS Inc.,
Chicago, IL, USA) was used for the statistical analyses
of this study. For the tests of normality, we used the
Kolmogorov–Smirnov test. The Mann–Whitney U or
the chi-square test was used for the comparisons of two
independent groups.
The patients were classified into clinical and
immunophenotypic subgroups for the comparisons. Clinical
subgroups were determined according to the existence
of splenomegaly, hepatomegaly, lymphadenopathy, low
body weight, and chronic complications of the lower
respiratory tract and the gastrointestinal system. The
immunophenotypic subgroups consisted of the patients
who had a low percentage of CD19+ B cells (less than or
equal to 2%) or a low CD4/CD8 ratio (less than or equal
to the lower reference limit of 0.8). Accordingly, while
SG-1 and SG-2 respectively include patients with or
without a low percentage of CD19+ B cells, SG-3 and SG-4
include patients with or without a low CD4/CD8 ratio.
The relationships among all parameters were shown by
the Spearman rank test or the Pearson test as appropriate.
A simple linear regression model was also used for the
relationships between the variables. P < 0.05 was accepted
as statistically significant.
3. Results
3.1. General characteristics of the patients and analyses
The CVID patients referred to our clinic originated from
different regions of Turkey. All of them were Caucasian and
they were not asked about ethnic origin. The demographic,
diagnostic, and treatment characteristics of the patients
with CVID are summarized in Table 1.
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Table 1. The demographic, diagnostic, and treatment
characteristics of the patients with CVID.
Characteristics
Sex (male/female)

19/12

Parental consanguinity
Current age (years)

4 (12.9)

a

28 (42)

b

Age at diagnosis (years) b

23 (48)

Delay in diagnosis (years) b

14 (42)

Graduation

a

Primary school

19 (61.3)

High school

12 (38.7)

Treatments at the first visit a

a

IVIG

7 (22.6)

Antibiotic prophylaxis

4 (12.9)

Surgical operation

3 (9.6)

n (%); b median (range).

An individualized dose of IVIG regimen at a certain
interval was started for newly diagnosed patients and the
patients who had only CVID diagnosis at their first visit
(in total 24 patients). While 4 patients with CVID were

receiving antibiotic prophylaxis at their first visit, we
started antibiotic prophylaxis for the 9 newly diagnosed
CVID patients. Thus, in total 13 patients with CVID
(41.9%) were given both IVIG and antibiotic prophylaxis
regimens after a certain follow-up period. Daily fulldose amoxicillin, trimethoprim/sulfamethoxazole, or
azithromycin was given every other day for prophylaxis.
Three different patients at their first visit had a surgery
history due to chronic complications of recurrent
infections. These were lung lobectomy, drainage of hepatic
abscess, and tonsillectomy.
The clinical characteristics of patients with CVID are
given in Table 2. The 10 warning signs of PID for adults
suggested by the Jeffrey Modell Foundation were used for
the clinical characteristics of the patients. It is noteworthy
that apart from these 10 warning signs other clinical
presentations of CVID, such as low body weight (45.2%),
urinary tract infections (41.9%), various dermatosis
(35.5%), oral aphthae (32.3%), and meningitis (6.5%),
were also observed in our patients.
While 14 patients (45.1%) had no comorbid condition,
17 patients (54.9%) had one or a few different comorbid
conditions. The frequency of gastrointestinal comorbidities
such as celiac-like disease, gastroduodenitis, and gastritis
was the highest (38.7%), followed by Hashimoto thyroiditis
(9.6%) and malignant comorbidities in remission
(9.6%) such as acute lymphoblastic leukemia (ALL),
papillary thyroid carcinoma, and Hodgkin disease. Other
comorbid conditions such as nephrotic syndrome with

Table 2. The clinical characteristics of patients with CVID.
Disease

Affected patients
(n)

Frequency
(%)

Sinusitis a

26

83.9

14

45.2

20

64.5

Chronic diarrhea with weight loss

6

19.3

Recurrent viral infections

31

100

Recurrent use of parenteral antibiotics

27

87.1

Recurrent skin abscesses

2

6.5

Persistent fungal infections

0

0

Otitis a
Pneumonia

a

b

Infection with tuberculosis like bacteria

0

0

Family history of PID c

3

9.6

According to warning signs of the Jeffrey Modell Foundation, frequencies of sinusitis and otitis
greater than or equal to 2 within 1 year and frequency of pneumonia once a year for more than
1 year were considered as significant for patients. b Colds, herpes, warts, condylomata. c Three
first-degree relatives of the patients had humoral immune defects, two of whom had selective
IgA deficiency (1 sister, 1 cousin) and 1 of whom had IgG2 deficiency (cousin).
a

3

MUŞABAK et al. / Turk J Med Sci
amyloidosis, type 2 diabetes, aplastic anemia, idiopathic
thrombocytopenic purpura (ITP), Behçet disease, and
reactive arthritis were separately observed in six different
patients.
All of the patients had chronic structural changes in the
lungs such as emphysema, atelectasis, or pleural thickening
according to high-resolution computed tomography, and
these findings were associated with bronchiectasis or
not at the percentages of 61.2% and 32.2%, respectively.
Other chronic complications of CVID in the patients
were enlargements of the spleen, the lymph nodes, and/
or the liver. Accordingly, the frequencies of splenomegaly,
lymphadenopathy, and hepatomegaly were 61.3% (19
patients), 48.4% (15 patients), and 22.6% (7 patients),
respectively, while 22.5% of the patients had none of these
complications. Isolated enlargements of the spleen and
lymph nodes but not of the liver were found in 19.3% and
16.1% of the patients, respectively. Involvements of two or
more of these organs were found in 38.7% of the patients.
Among the patients who underwent gastrointestinal
endoscopy and biopsy (11 patients), 6 (54.5%) had
nodular lymphoid hyperplasia, 3 (27.2%) had villous
atrophy, and 2 (18.1%) had lymphocytic infiltrates of the
mucosa. In addition, reactive hyperplasia was recorded in
histopathologic investigations of excisional biopsy samples
of the lymph nodes obtained from 3 of the 15 patients who
had lymphadenopathy. Neither incisional nor excisional
biopsy was performed in the patients with an enlarged
spleen or liver due to its invasiveness. Of the 11 skin biopsy
specimens of the patients with dermatitis, 7 (63.6%) were
histopathologically diagnosed as neutrophilic dermatosis.
Granuloma formation was not detected in any biopsy
specimens.
In investigation of stool specimens of the patients
with diarrhea, 3 (23.1%) cases of Giardia intestinalis, 3
(23.1%) of Candida, 2 (15.3%) of both Giardia intestinalis
and amoebae, and 2 (15.3%) of Escherichia coli were
determined using either light microscopy or cultures of
the specimens.
Various laboratory test results and immunological
measurements are given in Tables 3 and 4, respectively.
Leukocyte differential counts and biochemical tests of
the patients, except for one, were found to be normal
according to the reference ranges. The median levels of
ALP were higher than the upper reference limit. Increased
ALP levels were found in 17 patients (54.8%). All of the
patients had decreased levels of serum IgG and also low
levels of serum IgA and/or IgM at diagnosis. Isolated low
immunoglobulin levels in sera were found in 9.6% of the
patients, but low levels of 2 or 3 major immunoglobulins
in sera were respectively found in 29.0% and 61.2% of
the patients. Isolated low immunoglobulin levels were
detected only during the first admission of the patients
to our clinic who had already been diagnosed and treated
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with IVIG. While the median percentages of CD3+ T cells
and CD8+ T cells were within the reference ranges, the
median percentage of CD4+ T cells was low in the patients.
Accordingly, the patients had a low median ratio of CD4+
T cells to CD8+ T cells compared to the lower limit of the
reference range. Although the median percentage of B
cells of the patients was lower than the lower limit of the
reference range, the median absolute count of B cells of the
patients was normal. In addition, the patients had normal
median percentages and absolute counts of natural killer
(NK) cells and activated T cells (CD3+HLADR+).
The existence of chronic complications of the
gastrointestinal tract (nodular lymphoid hyperplasia,
villous atrophy, and lymphocytic infiltrates of the
mucosa) was positively correlated with splenomegaly,
hepatomegaly, and low body weight (r = 0.496, P = 0.005;
r = 0.363, P = 0.045; r = 0.477, P = 0.007, respectively).
Another significant association was found between daily
stool frequency and low body weight (r = 0.455, P = 0.010).
As expected, there was a positive relationship between
daily stool frequency and patients’ hematocrit levels.
Some typical correlations were separately observed
among immunoglobulin levels and lymphocyte subsets
(data not shown). Neither the percentage nor the absolute
count of CD19+ B cells was correlated with immunoglobulin
levels. However, IgG levels were negatively correlated with
the percentages of CD3+ and CD8+ T cells (r = 0.508, P =
0.004; r = 0.530, P = 0.002; respectively). Accordingly, there
was a positive correlation between IgG levels and CD4/
CD8 T cell ratio (r = 0.380, P = 0.035). The effect of CD4/
CD8 ratio on IgG production was described with the simple
linear regression model and was found to be statistically
significant (Figure 1a). On the other hand, serum B12 levels
were positively correlated with the percentage of CD3+ T
cells (r = 0.639, P = 0.006), but negatively correlated with
serum IgM levels and the percentage of CD19+ B cells
(r = 0.513, P = 0.035; r =0.566, P =0.018, respectively).
However, B12 levels were found to have an effect only on
the percentage of CD3+ T cells according to the simple
linear regression model (Figure 1b).
3.2. Comparisons of patient subgroups
There were no statistically significant differences
between male and female patients regarding the clinical
characteristics except for one. Urinary tract infection
was significantly more frequent in female patients than
in male patients (75% vs. 21.1%: P = 0.008). Diagnostic
delay was predominant in the patients who were educated
at a primary school level compared to the patients who
were educated at a high school level. On the other hand,
neutrophilic dermatoses in better educated patients were
more frequent than in less educated patients. However,
these differences were not statistically significant (data not
shown).

MUŞABAK et al. / Turk J Med Sci
Table 3. The laboratory measurements of the patients with CVID.
Quantitative tests

n

Median (range)

Reference ranges

WBCs (cells/µL)

31

7700 (23,500)

(4100–11,200)

Lymphocytes (%)

31

28.1 (42.6)

(18.8–50.8)

Lymphocytes (cells/µL)

31

1780 (4830)

(1200–3600)

Monocytes (%)

31

6.2 (7.5)

(2.0–12.2)

Monocytes (cells/µL)

31

372 (1126)

(300–900)

Granulocytes (%)

31

62.3 (44.2)

(40.9–79.3)

Granulocytes (cells/µL)

31

4203 (21,730)

(1900–7100)

AST (U/L)

31

25 (50)

(10–35)

ALT (U/L)

31

19 (73)

(10–35)

ALP (U/L)

31

124 (293)

(30–120)

GGT (U/L)

31

28 (75)

(7–38)

B12 (pg/mL)

31

349 (529)

(197–866)

Qualitative tests

na

%

References

Anti-TPO b

4

19

Negative

HBsAg

0

0

Negative

Anti-HCV

0

0

Negative

Anti-HIV

0

0

Negative

Anti-HBs c

4

12.9

Negative

A

11

35.5

NA

B

7

22.6

NA

AB

3

9.7

NA

10

32.3

NA

21

75

1/32–1/512

Leukocyte differential count

Biochemical tests

Viral markers

Blood groups

O
Isohemagglutinin titer

d

e

Anti-TPO: Thyroid peroxidase antibody; HBsAg: hepatitis B surface antigen; Anti-HCV:
hepatitis C antibody; Anti-HIV: human immunodeficiency virus antibody; Anti-HBs: hepatitis
B antibody; NA: not applicable.
a
The number of patients who had positive test results. b Anti-TPO was investigated in 21
patients. c The patients with anti-HBs positivity had no history of vaccination. While 4
anti-HBs-positive patients were diagnosed in other centers and 3 of them were under IVIG
treatment, the remaining 3 patients had positive serology for this marker before IVIG treatment.
d
Isohemagglutinin titer was measured in 28 patients who had O, A, or B blood groups. e The
number of patients who had a low isohemagglutinin titer (<1/32).
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Table 4. The immunological measurements of the patients with CVID.

a

Immunological tests

n

Median (range)

n (%) a

Reference ranges

IgM (g/L)

31

0.2 (3.7)

22 (70.9%)

(0.46–3.04)

IgA (g/L)

31

0.2 (2.2)

29 (93.5 %)

(0.82–4.53)

IgG (g/L)

31

4.6 (6.4)

31 (100 %)

(7.51–15.6)

IgE (IU/mL)

31

6 (115)

-

(0–85)

C3c (g/L)

31

1.2 (1.3)

3 (9.6 %)

(0.79–1.52)

C4 (g/L)

31

0.2 (0.5)

4 (12.9 %)

(0.16–0.38)

CD3 (%)

31

78.1 (36.3)

3 (9.6)

(63–85)

CD3 (cells/µL)

23

1101 (1848)

3 (13.0)

(700–2100)

CD4 (%)

31

30.8 (48.9)

19 (61.2)

(4–64)

CD4 (cells/µL)

23

370 (1543)

9 (39.1)

(300–1400)

CD8 (%)

31

38.7 (58.1)

1 (3.2)

(19–48)

CD8 (cells/µL)

23

677 (1851)

2 (8.6)

(200–900)

CD4/CD8 (%)

31

0.7 (2.3)

16 (51.6)

(0.8–3.3)

CD19 (%)

31

6.3 (23.8)

15 (48.3)

(7–23)

CD19 (cells/µL)

23

112 (2870)

10 (43.4)

(100–500)

CD3-CD16+56+ (%)

31

9.1 (26.9)

9 (29.0)

(6–29)

CD3-CD16+56+ (cells/µL)

23

139 (288)

3 (13.0)

(78–470)

CD3+HLADR+ (%)

31

6.3 (36.7)

7 (22.5)

(3.6–25.9)

CD3+HLADR+ (cells/µL)

23

145 (686)

-

(30–500)

CD45 (%)

31

95.6 (9.3)

-

(88–100)

: Patients had decreased levels according to reference ranges.

No statistically significant difference was found
between male and female patients with CVID regarding the
measurements of leukocyte differential counts, biochemical
tests, and immunological parameters. The comparisons of
parametric tests were also not significantly different from
one another among the clinical subgroups of the patients
according to clinical characteristics, except for two. The
first subgroup, including the patients with low body weight,
had a lower CD4/CD8 T cell ratio than the subgroup
with normal body weight [median (range): 0.4 (2.2) vs.
1.2 (2.3)] (Figure 2a). The second one, the patients with
hepatomegaly, had higher AST and GGT levels than those
without hepatomegaly [median (range): 39 (44) vs. 23 (34);
57 (65) vs. 25 (63); respectively] (Figures 2b and 2c).
The patients with a low percentage of CD19+ B cells
(SG-1) had lower IgM levels but a higher percentage of
CD3+HLADR+ T cells than the remaining patients (Table
5; Figures 2d and 2e). In addition, a lower level of IgG and
lower percentage of CD19+ B cells but a higher percentage
of CD3+HLADR+ T cells were found in the patients who
had a low CD4/CD8 ratio (SG-3) than the remaining
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patients (Table 5; Figures 2f–2h). The differences in the
comparisons of other nonparametric and parametric test
results did not reach statistical significance between these
patient subgroups.
4. Discussion
CVID is a prevalent form of PID in Caucasian populations
(8). All of our patients were Caucasian and originated
from different regions of Turkey. While parental
consanguinity in our patients was found to be 12.9%,
this rate was found to be 5.4%, 7%, and 8% in the studies
reported by Oksenhendler et al., Malphettes et al., and
Aghamohammadi et al., respectively (9–11). The highest
percentage for consanguineous marriage was given as 30%
in Ardeniz et al.’s study (12).
In Carvalho et al.’s study, the ages at diagnosis and
the first symptoms were respectively found to be 22 and
12 years in patients with CVID (13), similar to those of
our patients. In Ardeniz et al.’s study, the median values of
age at diagnosis and delay in diagnosis were respectively
33 (range: 17–73) years for females and 28 (range: 13–49)

MUŞABAK et al. / Turk J Med Sci

P

P

Figure 1. P-P plots of the relationships between IgG levels and the ratio of CD4/CD8 (a) and B12 levels and the percentage of CD3+ T
cells (b).

years for males, and 15 (range: 1–32) years for females
and 8 (range: 1–31) years for males (12). Similarly, these
parameters were respectively 47 (range: 13–72) years
vs. 30 (range: 5–56) years in females and males, and 7.0
(range: 1–45) vs. 3.0 (range: 0.8–30) years in females and
males in Thickett et al.’s study (14). The findings of the
last two studies including a small number of patients are
comparable to those of the EUROClass trial and the DEFI
study including large series (4,9).
Since the clinical spectrum of CVID varies from mild
to severe, some cases are easily missed by physicians.
However, awareness of this disorder is also at undesired
levels among people in general regardless of the level
of development of their countries (15). Therefore, we
categorized our patients into 2 educational levels and
compared them with each other with regard to diagnostic
delay. However, we could not find any significant difference
between the patient subgroups.
The dose of IVIG used for the treatment of our patients
was changed between 400 and 600 mg/kg (median: 600
mg/kg) every 3 to 4 weeks. The dose was adjusted based on
recurrence of infection and the IgG levels of our patients.
In some reports from a single-center case series, IVIG
dosage and the range of frequencies were similar to those
of our study (11,12,14). However, the data of multicenter
cohorts (EUROClass and DEFI) showed that various
doses of IVIG (median: 129–750 mg/kg monthly) have
been used for CVID treatment (4,9).

Prophylactic antibiotic therapy was required in 41.9%
of our patients who had persistent infections despite IVIG
therapy. As in our study, 43% of the patients in Thickett
et al.’s study were given antibiotic therapy in continuously
or monthly rotating manners (14). However, the rate of
prophylactic antibiotic usage of the patients with CVID
in Ardeniz et al.’s study was found to be 21.7% (12). No
additional major surgery was needed in our patients
after the optimal dose of IVIG therapy and/or antibiotic
prophylaxis.
The frequencies of clinical characteristics of our
patients on admission were either slightly or considerably
different from those of other reports (9,12,13). Briefly,
in these reports and the current study, the ranges of
frequencies of sinusitis, otitis, and pneumonia are between
63% and 91.3%, 35.2% and 91.3%, and 58% and 64.5%,
respectively. Patients with chronic diarrhea (without
weight loss and/or malabsorption) were more frequent in
our study and in that of Ardeniz et al. (38.7%, 52.1%) than
in those of Oksenhendler et al. and Carvalho et al. (23%,
29%). As in the other reports, Giardia was found to be the
main causative agent in our patients with chronic diarrhea
(8). Since these clues are acquired from the patients by
investigating standard signs, these data mostly depend
on subjective information and the physician’s experience.
We therefore think that this may be a reason for the
differences in the frequencies of the clinical signs noted in
the literature.
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Figure 2. The differences in laboratory measurements between subgroups of patient with CVID. Patients were subdivided
according to clinical or immunophenotypic properties. Accordingly, (a) shows the comparisons of patients with or without
low body weight; (b) and (c) show comparisons of patients with or without hepatomegaly; (d) and (e) show comparisons of
the patients with or without low percentage of CD19+ B cells; and (f), (g), and (h) show the comparisons of the patients with
or without low CD4/CD8 ratio. Boxes show the ranges of 1st and 3rd quartiles and extreme values. Horizontal bars represent
median values. The differences between two groups were evaluated by the Mann–Whitney U test. P-values are indicated
above the boxes when a level of significance of P < 0.05 was reached in the comparisons of study groups. SG: Subgroup.

We indeed found some additional clinical signs,
frequencies of which were nonnegligible in the course
of CVID. The main ones were urinary tract infections,

8

various dermatosis, oral aphthae, and meningitis. In
the current study, the female patients had a higher
frequency of urinary tract infection than male patients,
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Table 5. Comparisons between the subgroups of patients with CVID.
SG-1

SG-2

SG-3

SG-4

n=9

n = 22

n = 14

n = 17

IgM (g/L)

0.17 (0.35)

0.23 (3.76)

0.035

0.18 (3.76)

0.21 (1.09)

0.164

IgA (g/L)

0.22 (0.46)

0.24 (2.17)

0.930

0.21 (0.59)

0.25 (2.17)

0.196

IgG (g/L)

2.7 (5.48)

4.7 (6.17)

0.407

2.9 (6.47)

4.9 (5.18)

0.023

CD3 (%)

84.4 (21.4)

75.8 (36.3)

0.016

83.6 (28.4)

75.2 (34.3)

0.059

CD4 (%)

22.1 (38.0)

32.3 (48.9)

0.408

21.5 (23.7)

37.1 (40.0)

<0.001 a

CD8 (%)

52.0 (31.2)

35.0 (58.1)

0.052

54.3 (40.2)

32.6 (28.6)

<0.001 a

CD4/CD8 (%)

0.42 (1.18)

0.94 (2.31)

0.107

0.40 (0.46)

1.26 (1.93)

<0.001 a

CD19 (%)

1.2 (1.7)

8.6 (20.6)

<0.001 a

2.8 (16.2)

8.4 (23)

0.011

CD3+HLADR+ (%)

10.3 (34.8)

4.6 (31.7)

0.026

9.3 (34.8)

4.3 (31.7)

0.028

P

a

P

Values are given as median (range). The patients were divided into the subgroups (SGs) according to their percentage of CD19+ B cells
or CD4/CD8 ratio. While SG-1 and SG-2 included patients with or without a low percentage of CD19+ B cells, respectively, SG-3 and
SG-4 included patients with or without a low CD4/CD8 ratio. a : Natural results for immunophenotyping due to using a gating strategy
in flow cytometry. Values are given in bold when the level of significance is less than 0.05 in comparisons of study groups.

as in a healthy population (16). In Patuzzo et al.’s study,
the frequencies were found to be 30.4% for urinary tract
infection and 4.3% for both lichen planus and meningitis
(17). While 2 patients (8.6%) had measles encephalitis and
pneumococcal meningitis history in Ardeniz et al.’s study,
the frequency of meningitis was 8% in Oksenhendler et
al.’s study (9,12). One patient (4.3%) also had perivascular
dermatitis in the former study. While we predominantly
identified neutrophilic dermatosis in our patients,
autoimmune disorders such as vitiligo and alopecia were
reported as the most common forms of skin involvement
in CVID in other reports (5,8). Notably, there are only 3
reports in the literature showing the relationship between
CVID and aphthous-like ulceration (18–20). The latest
one was published by Meighani et al., who reported that
5 patients with CVID (23.8%) in their study had oral
aphthae (20).
We found that the most common comorbidity associated
with CVID was chronic inflammatory diseases of the
gastrointestinal tract, followed by autoimmune thyroiditis
and various malignant disorders in remission. These
conditions developing in the course of CVID were already
shown in many previous studies (21). The frequency of
autoimmune thyroid disease shown by anti-TPO was 19%
in our patients. The frequencies of thyroid autoantibodies
were detected in a wide range in other studies on CVID
(5,9,17,21). Although autoimmune cytopenia is one of
the most common comorbidities associated with CVID,
we diagnosed ITP only in 1 patient. It was reported in a

multicenter study by Chapel et al. that the prevalence of
autoimmune cytopenias in their study group was 7% for
ITP, 4% for autoimmune hemolytic anemia (AIHA), and
1% for neutropenia (22). The EUROClass study group
showed that the prevalence of autoimmune cytopenia was
20.2% in their patients (4).
As in other reports, chronic complications of CVID
involving the lungs, spleen, lymph nodes, and/or liver
were observed in some of our patients. Bronchiectasis
frequency in our patients was close to that in the patients
of Thickett et al. (61.2% vs. 68.1%) (14), but significantly
higher than those in the patients of Oksenhendler et al.
(37%), Patuzzo et al. (26.1%), and Chapel et al. (25.1%)
(9,17,22). Similarly, the rate of patients with splenomegaly
in our study was 61.3%, but rates were 38%, 30.4%, and
30% in the former 3 studies, respectively (9,17,22), and
40.5% in Wehr et al.’s study (4). We found the highest
lymphadenopathy frequency in our patients (48.4%) as
compared to those of Wehr et al., Chapel et al., and Patuzzo
et al. (26.2%, 30%, and 43.4%, respectively) (4,17,22). The
frequency of hepatomegaly that we found in our patients
was also the highest compared to those that other studies
found, which were between 0% and 15% (22).
In our study, splenomegaly and hepatomegaly either
coexisted in the same patient or existed separately. In
addition, enlargements of these organs were associated
with each other, low body weight, and chronic
complications of the gastrointestinal tract. There were
also positive relationships between the last 2 features
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and between daily stool frequency and low body weight.
Ward et al. found similar results in their study suggesting
that splenomegaly and hepatomegaly developed either
jointly or separately in patients with CVID (23). They also
showed a strong association between nodular regenerative
hyperplasia of the liver and lymphoproliferation in their
patients. Contrary to our findings, in Ghoshal et al.’s report,
although all patients with hypogammaglobulinemia had
diarrhea and weight loss, no significant association was
determined between daily stool frequency and low body
weight (24).
Histopathologic findings in biopsy specimens taken
from the gastrointestinal tract of our patients were similar
to those in other reports showing lymphoid hyperplasia,
villous atrophy, and lymphocytic infiltration in the lamina
propria (9,22).
Neither viral hepatitis nor HIV infection was found in
our patients. Viral hepatitis induced by hepatitis C virus,
but not hepatitis B virus, was reported in patients with
CVID in the studies by Oksenhendler et al. and Ardeniz
et al. (9,12).
In our study, the levels of 3 major immunoglobulin
isotypes in the sera of patients with CVID were
significantly lower than the lower limits of their ranges.
In the EUROClass trial, IgG, IgA, and IgM levels were
found to be significantly decreased in CVID patients,
but the percentages of the patients with low/undetectable
IgA and IgM levels were higher than those of our patients
(50% vs. 29%, 79% vs. 22%, respectively). The results of
the DEFI trial are compatible with these results, stating
that respectively 41%, 40%, and 15% of patients with
CVID at diagnosis had decreased IgG, IgA, and IgM levels
according to certain reference ranges (9).
No relation was shown between immunoglobulin
levels and clinical findings in our study. A similar finding
was reported by Chapel et al., stating that very low serum
IgG levels are not associated with increased numbers of
severe infections prior to diagnosis (22).
We mainly found decreased percentages of CD4+ T cells
in our patients. Accordingly, the CD4/CD8 ratio was lower
than its lower reference limit. T-cell subset alteration in
CVID was previously shown in Ardeniz et al.’s study, stating
that 20 cases had decreased CD4+ T cell count but 6 had
increased CD4+ T cell count (12). In another study, Batman
et al. reported that a significant reduction in the number
of naive CD4 T cells existed in CVID patients due to the
lack of the replenishment of the CD4 T-cell pool by new
thymic-derived cells (25). In an older study, Giovannetti
et al. mentioned the contraction of CD4 naive T-cell pools
in CVID by reduced thymic output and increased T-cell
turnover and apoptosis. The results of these studies seem to
be comparable to ours and strongly explain the reason for
the inversion of the CD4/CD8 ratio (26).
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In addition, serum IgG levels of our patients were
positively correlated with the CD4/CD8 ratio but
negatively correlated with CD8+ T cells. This relationship
may be contributed to impaired IgG production besides
defective molecular interaction between T cells and B cells
as shown in the investigations by de Witt et al. and Bouaziz
et al. (27,28). Therefore, we can speculate that the CD4/
CD8 ratio is a risk factor for poor outcome of CVID via
the suppression of humoral immunity. The ratio of CD4+
T cells to CD8+ T cells was low in our patients with a low
body weight. These data are new knowledge for CVID and
similar findings were reported in studies in which patients
with HIV infection were the subject of research (29).
We observed that the patients with CVID had a
decreased percentage of B cells and about half of them had
a decreased B-cell percentage and/or absolute count. This
is an important point because patients with CVID in large
cohorts were classified into subgroups based on clinical
course and B-cell percentage and then B-cell subsets (4).
In the current study, although the percentages and
absolute counts of NK cells and activated T cells were
within the normal limits, these cell subsets were found
to be low in some patients with CVID. A similar result
was earlier reported by Aspalter et al., suggesting that
the patients had reduced absolute CD3-CD16+ NK cell
numbers compared with normal subjects (30).
Decreased B cells associated with decreased IgM
production but increased T-cell activity were found in
our CVID patients (SG-1). Additionally, the patients
with a diminished CD4/C8 ratio (SG-3) had low IgG
production and B cells but increased T cell activity. In
other words, on the one hand, both humoral and cellular
immune responses were weakened in the patients with
CVID. On the other hand, their T cells were on alert.
This means that immune activation is maintained in
CVID patients at a certain level and insidiously leads to
chronic complications of the disease. Baumert et al. earlier
categorized patients with CVID based on the CD4/CD8
ratio and found that the patients with a low ratio had
increased CD4+ T cells bearing the activation marker
HLADR (31). The study by Savasan et al. supports this
hypothesis that Fas-mediated elimination of activated T
lymphocytes was shown in children with Evans syndrome
who had hypogammaglobulinemia (32). It is well known
that Evans syndrome is characterized by ITP and AIHA,
and it is one of the long-term complications resulting from
immune dysregulation in CVID (33).
We found that serum B12 levels were related to an
increased T-cell percentage, but decreased serum IgM
levels and B-cell percentages. Tamura et al. reported
decreased T cell subsets in B12 deficiency and emphasized
the regulatory role of B12 on cellular immunity (34).
On the other hand, it is well known that increased
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serum B12 levels are reliable biomarkers of autoimmune
lymphoproliferative syndrome (ALPS) and can be
used to differentiate between ALPS and CVID (35,36).
However, Roberts et al. also found increased serum B12
levels in CVID patients compared to healthy controls
(36). We investigated the possible relationship between
lymphoproliferation and serum B12 levels but failed to
show one.
In our study, the liver function test results for AST
and GGT were higher in the patients with hepatomegaly
than in those without hepatomegaly. In Ward et al.’s study,
abnormal liver function tests (especially for ALP) and
hepatomegaly were present together in some patients with
CVID and were associated with elevated GGT (23).
In conclusion, CVID has many clinical and laboratory
signs having logical relationships with one another.
The clinical presentations of CVID are more complex
in adults than in children. Sometimes the disease
insidiously progresses and threatens patients’ life. The

chronic complications of CVID and associated comorbid
conditions determine the severity and prognosis of the
disease. Therefore, all of these associations should be
clarified for solving the pathogenesis of CVID and its
effective treatment. For this purpose, authors should share
and discuss their own experiences with CVID by comparing
them with the data obtained from all other studies. On
the other hand, every country should establish its own
database and bring it into use for clinical immunologists
as soon as possible. It should not be forgotten that this
insidious disease is more common and dangerous than
estimated, especially in adulthood. An early and accurate
diagnosis of CVID can improve quality of life, reduce the
morbidity and mortality of patients, and prevent economic
losses due to wrong treatments.
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